Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.36 |
| ▸ | SLC2A2 | P11168 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | PRNP | P04156 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15914940 | 0.86 | SLC2A1 (0.40) | SLC2A1GRIA1SLC2A2SCN9AKCNK3 | |
| SCHEMBL15914729 | 0.81 | CYP3A4 (0.36) | SLC2A1TTKCHEK1CYP3A4MKNK1 | |
| SCHEMBL12819176 | 0.80 | SLC2A1 (0.61) | SLC2A1SLC2A2KCNK3KCNK9 | |
| SCHEMBL15915223 | 0.80 | SLC2A1 (0.35) | SLC2A1SLC2A2TTKKCNK3KCNK9 | |
| SCHEMBL15914693 | 0.79 | SLC2A1 (0.51) | SLC2A1GRIA1SLC2A2KCNK3KCNK9 | |
| SCHEMBL15914564 | 0.78 | SLC2A1 (0.42) | SLC2A1SLC2A2TOP2ATOP2BMKNK1 | |
| SCHEMBL15914497 | 0.75 | SLC2A1 (0.38) | SLC2A1KDM5BKCNK3KCNK9CYP3A4 | |
| SCHEMBL15914583 | 0.74 | CYP3A4 (0.35) | SLC2A1TTKCHEK1CYP3A4MKNK1 | |
| SCHEMBL15914643 | 0.71 | SLC2A1 (0.48) | SLC2A1SLC2A2TOP2ACYP3A4MKNK1 | |
| SCHEMBL15914849 | 0.69 | MKNK1 (0.39) | SLC2A1KCNK3KCNK9CYP3A4MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM TECHNOLOGY TRANSFER GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | HIF1A, HIF1AN, EGLN3 | SLC2A1 1235/4885GRIA1 3203/4885SLC2A2 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.